Switch theme
Sign up to access all valuation multiples
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
1946
2.2K+
LTM Revenue $839M
LTM EBITDA $222M
$3.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Laboratorios Rovi has a last 12-month revenue (LTM) of $839M and a last 12-month EBITDA of $222M.
In the most recent fiscal year, Laboratorios Rovi achieved revenue of $858M and an EBITDA of $233M.
Laboratorios Rovi expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Laboratorios Rovi valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $839M | XXX | $858M | XXX | XXX | XXX |
| Gross Profit | $533M | XXX | $537M | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 63% | XXX | XXX | XXX |
| EBITDA | $222M | XXX | $233M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| EBIT | $195M | XXX | $202M | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $150M | XXX | $154M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 18% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $79.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Laboratorios Rovi's stock price is EUR 54 (or $61).
Laboratorios Rovi has current market cap of EUR 2.8B (or $3.1B), and EV of EUR 2.9B (or $3.2B).
See Laboratorios Rovi trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.2B | $3.1B | XXX | XXX | XXX | XXX | $2.90 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Laboratorios Rovi has market cap of $3.1B and EV of $3.2B.
Laboratorios Rovi's trades at 3.7x EV/Revenue multiple, and 13.8x EV/EBITDA.
Equity research analysts estimate Laboratorios Rovi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Laboratorios Rovi has a P/E ratio of 20.9x.
See valuation multiples for Laboratorios Rovi and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.1B | XXX | $3.1B | XXX | XXX | XXX |
| EV (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 3.7x | XXX | XXX | XXX |
| EV/EBITDA | 14.5x | XXX | 13.8x | XXX | XXX | XXX |
| EV/EBIT | 16.5x | XXX | 16.0x | XXX | XXX | XXX |
| EV/Gross Profit | 6.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 20.9x | XXX | 20.3x | XXX | XXX | XXX |
| EV/FCF | 36.6x | XXX | 37.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLaboratorios Rovi's last 12 month revenue growth is 3%
Laboratorios Rovi's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Laboratorios Rovi's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Laboratorios Rovi's rule of X is 34% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Laboratorios Rovi and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | -12% | XXX | XXX | XXX |
| Rule of 40 | 33% | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Laboratorios Rovi acquired XXX companies to date.
Last acquisition by Laboratorios Rovi was XXXXXXXX, XXXXX XXXXX XXXXXX . Laboratorios Rovi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Laboratorios Rovi founded? | Laboratorios Rovi was founded in 1946. |
| Where is Laboratorios Rovi headquartered? | Laboratorios Rovi is headquartered in Spain. |
| How many employees does Laboratorios Rovi have? | As of today, Laboratorios Rovi has 2.2K+ employees. |
| Who is the CEO of Laboratorios Rovi? | Laboratorios Rovi's CEO is Mr. Juan Lopez-Belmonte Encina. |
| Is Laboratorios Rovi publicy listed? | Yes, Laboratorios Rovi is a public company listed on MAD. |
| What is the stock symbol of Laboratorios Rovi? | Laboratorios Rovi trades under ROVI ticker. |
| When did Laboratorios Rovi go public? | Laboratorios Rovi went public in 2007. |
| Who are competitors of Laboratorios Rovi? | Similar companies to Laboratorios Rovi include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Laboratorios Rovi? | Laboratorios Rovi's current market cap is $3.1B |
| What is the current revenue of Laboratorios Rovi? | Laboratorios Rovi's last 12 months revenue is $839M. |
| What is the current revenue growth of Laboratorios Rovi? | Laboratorios Rovi revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Laboratorios Rovi? | Current revenue multiple of Laboratorios Rovi is 3.8x. |
| Is Laboratorios Rovi profitable? | Yes, Laboratorios Rovi is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Laboratorios Rovi? | Laboratorios Rovi's last 12 months EBITDA is $222M. |
| What is Laboratorios Rovi's EBITDA margin? | Laboratorios Rovi's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Laboratorios Rovi? | Current EBITDA multiple of Laboratorios Rovi is 14.5x. |
| What is the current FCF of Laboratorios Rovi? | Laboratorios Rovi's last 12 months FCF is $88.0M. |
| What is Laboratorios Rovi's FCF margin? | Laboratorios Rovi's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Laboratorios Rovi? | Current FCF multiple of Laboratorios Rovi is 36.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
